Finance

U.S. prosecutors consider more charges against ex-CEO Shkreli

Martin Shkreli, former CEO of Turing Pharmaceuticals LLC, appears before a House Oversight and Government Reform hearing on Capitol Hill in Washington in this file picture taken February 4, 2016. REUTERS/Joshua Roberts/Files Thomson ReutersFile photo of Shkreli, former CEO of Turing Pharmaceuticals LLC, appearing before a hearing in Washington

NEW YORK (Reuters) – Former drug executive Martin Shkreli, who last year became a lightning rod for outrage over soaring prescription drug prices, may face additional U.S. charges of securities fraud, a federal prosecutor said on Tuesday.

More charges related to Shkreli’s involvement with biopharmaceutical company Retrophin Inc could be filed within a month, Assistant U.S. Attorney Winston Paes said at a hearing in federal court in Brooklyn, New York.

(Reporting by David Ingram; Editing by Nick Zieminski)

Read the original article on Reuters. Copyright 2016. Follow Reuters on Twitter.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

1 × 4 =

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Most Popular

To Top